MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
-0.55 (-2.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close22.24
Bid21.51 x 4000
Ask22.09 x 1100
Day's range21.66 - 22.90
52-week range16.63 - 39.59
Avg. volume7,424,292
Market cap11.189B
Beta (3Y monthly)2.05
PE ratio (TTM)355.57
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2007-06-27
1y target estN/A
Trade prices are not sourced from all markets
Press releases
  • Business Wire

    Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS.

  • PR Newswire

    Mylan Launches Hulio™ (Biosimilar Adalimumab) in Markets Across Europe

    HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe. Mylan President Rajiv Malik commented: "We're proud of our strategic partnership with Fujifilm Kyowa Kirin Biologics and the strong collaboration of our science and technology teams to bring Hulio to market for patients. As the cost of healthcare continues to rise around the world, we know the important role that biosimilars play to ensure patients can access the medicines they need.

  • We're sorry, but this is all we were able to find on this topic.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more